Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00767975

Acronym

LTBI_prison

Enrollment

2384

Registered

2008-10-07

Start date

2008-01-31

Completion date

2010-11-30

Last updated

2010-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Brief summary

LTBI Treatment is effective in prison

Detailed description

LTBI treatment will be conducted in a prison with either isoniazid or rifampin

Interventions

DRUGisoniazid , randomized, open label

isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)

DRUGrifampin, randomized, open label

rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* all people who is LTBI, and have ability to sign the informed concent

Exclusion criteria

* previously adverse effect from anti-TB medication complete treatment of TB in the pass; active TB AST, ALT \> 3 times of normal limit platelet \< 150 k/mm3 T-bil \> 2 times of normal limit

Design outcomes

Primary

Measure	Time frame
COMPLETE RATE OF LTBI TREATMENT	1.5 year

Secondary

Measure	Time frame
Efficacy	3 year

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026